Insider Trading March 6, 2026

BrightSpring Health Executive Disposes $1.23M in BTSG Stock Amid Active Analyst Coverage

Chief of Staff Lisa Nalley sells 30,000 shares as the stock trades near its 52-week high while the company navigates analyst upgrades and a large secondary offering

By Leila Farooq BTSG
BrightSpring Health Executive Disposes $1.23M in BTSG Stock Amid Active Analyst Coverage
BTSG

Lisa A. Nalley, BrightSpring Health Services' Chief of Staff and SVP of Human Resources, sold 30,000 shares of company stock on March 4, 2026, generating roughly $1.23 million. The transactions, disclosed via an SEC Form 4, included option exercises and subsequent equity grants. The stock has climbed sharply over the past year and sits close to its 52-week high amid multiple analyst upgrades and a 20 million-share secondary offering by certain stockholders.

Key Points

  • BrightSpring SVP Lisa A. Nalley sold 30,000 shares on March 4, 2026, at $41.15 per share, totaling approximately $1.23 million.
  • Nalley exercised 30,000 options at $6.37 per share for $191,100 on March 4, 2026, received 21,354 restricted stock units on March 5, 2026, and was granted 52,344 options exercisable at $41.77 on March 5, 2026.
  • Company shares are trading near a 52-week high of $44.87 after a 137% gain over the past year; BrightSpring's market value stands at $8.59 billion, amid analyst upgrades and a 20 million-share secondary offering priced at $41.15 per share.

BrightSpring Health Services, Inc. (NASDAQ: BTSG) reported an insider sale and a set of related equity transactions for a senior executive in early March 2026. According to a Form 4 filed with the Securities and Exchange Commission, Lisa A. Nalley, who serves as Chief of Staff and Senior Vice President, Human Resources, sold 30,000 shares of common stock on March 4, 2026, at $41.15 per share — a transaction that amounted to approximately $1.23 million.

The Form 4 filing details additional activity by Nalley on March 4 and March 5, 2026. On March 4, she exercised options to acquire 30,000 shares of BrightSpring common stock at an exercise price of $6.37 per share, for a total outlay of $191,100. The following day, March 5, Nalley received 21,354 restricted stock units with a zero-dollar acquisition price noted in the filing. Also on March 5, she was granted 52,344 stock options exercisable at $41.77.

These transactions come while BTSG shares are trading near a 52-week high of $44.87, following a 137% gain over the prior 12 months. The company carries a market value of $8.59 billion.


Analyst coverage and company financials have been active components of the recent market narrative around BrightSpring. The company reported fourth-quarter fiscal 2025 results in which revenue and EBITDA exceeded FactSet consensus estimates. Those results prompted BTIG to reiterate a Buy rating with a $55 price target. TD Cowen raised its price target to $49, citing the company’s momentum, while Mizuho lifted its price target to $50 and increased its 2026 and 2027 adjusted earnings per share and EBITDA estimates by 14% and 16%, respectively, additionally publishing estimates for 2028.

At the same time, InvestingPro analysis referenced in the filing indicates that BTSG may be overvalued at current market levels. The filing notes that six analysts have revised earnings upward for the company. For investors seeking deeper research, the Pro Research Report for BTSG offers further analysis plus 12 additional ProTips and coverage that extends across more than 1,400 U.S. equities.

Market activity also includes a secondary offering announced by certain stockholders. The offering was priced at $41.15 per share for 20 million shares and involves selling stockholders that include an affiliate of Kohlberg Kravis Roberts & Co. L.P. and members of management. The company has stated it will not sell any shares in this offering and will not receive proceeds, as all sale proceeds will go to the selling stockholders.


Overall, the filings and disclosures present a concentrated period of equity activity for BrightSpring, combining insider option exercises and sales, analyst target revisions, financial outperformance for the latest quarter, and a sizeable secondary placement by existing stockholders.

Risks

  • Insider selling and a large secondary offering by existing stockholders could increase near-term supply pressure on the stock - impacting the healthcare services sector and BTSG share liquidity.
  • InvestingPro analysis flagged potential overvaluation at current levels, introducing valuation risk for investors evaluating exposure to the company and the broader healthcare services equity segment.
  • Although recent quarter revenue and EBITDA beat consensus, future expectations were adjusted by analysts (including raised estimates and new longer-term forecasts), creating execution and forecast risk tied to the company’s ability to meet elevated market projections.

More from Insider Trading

Delek US Director Executes $1.3M Sale Under 10b5-1 Plan as Shares Near 52-Week Peak Mar 6, 2026 ASP Isotopes COO Sells $45,894 in Stock as Company Advances M&A and Leadership Moves Mar 6, 2026 Delek US Director Disposes $230,508 in Shares; Company Posts Strong EPS Beat in Q4 2025 Mar 6, 2026 Rimini Street CEO Executes Sell-to-Cover, Donates Large Block; Tidewater Partnership Expands Globally Mar 6, 2026 Civeo SVP Sells 4,000 Shares for $114,560 as Stock Trades Near 52-Week High Mar 6, 2026